Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

Delphine ReaShanti AmeMarc BergerJean-Michel CayuelaAude CharbonnierValérie CoiteuxPascale Cony-MakhoulViviane DubruilleStéphanie DulucqGabriel EtienneLaurence LegrosFranck NicoliniCatherine Roche-LestienneMartine Escoffre-BarbeMartine GardembasAgnès Guerci-BreslerHyacinthe Johnson-AnsahFrançoise Rigal-HuguetPhilippe RousselotFrançois-Xavier Mahonnull null

Published in: Cancer (2018)

This work presents consensus statements with the aim of guiding physicians and biologists by means of pragmatic recommendations for safe TKI discontinuation in daily practice. Cancer 2018;124:2956-63. © 2018 American Cancer Society.

Keyphrases

chronic myeloid leukemia
clinical practice
papillary thyroid
primary care
squamous cell
healthcare
lymph node metastasis
physical activity
clinical trial
childhood cancer
study protocol
young adults
quality improvement
advanced non small cell lung cancer